Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2023 | ADAPT trial: Endocrine + ribociclib vs. chemotherapy in HR+/HER2- early breast cancer

Rick Baehner, MD, from Exact Sciences, discusses the innovative the Phase III ADAPTcycle (NCT04055493) trial presented at the San Antonio Breast Cancer Symposium (SABCS). The trial combines standard clinical-pathologic factors, the 21-gene recurrence score result, and the dynamic biomarker Ki-67. It focuses on patients with select clinical-pathologic factors, intermediate-risk recurrence score results, and evidence of endocrine therapy responsiveness, indicated by a Ki-67 decrease after a 2 to 4-week window of endocrine therapy. The trial aims to randomize these patients to standard chemotherapy or endocrine therapy plus a CDK4/6 inhibitor. The goal is to identify a subset of patients with specific recurrence score criteria and endocrine therapy responsiveness, allowing for chemotherapy de-escalation in favor of a CDK4/6 inhibitor and endocrine therapy. This interview took place at the SABCS congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.